SI-BONE (SIBN) Competitors

SI-BONE (NASDAQ:SIBN) and Enovis (NYSE:ENOV) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Which has stronger valuation & earnings, SIBN or ENOV?

Enovis has higher revenue and earnings than SI-BONE. Enovis is trading at a lower price-to-earnings ratio than SI-BONE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SI-BONE	$138.89M	5.06	-$43.34M	-$0.92	-18.22
Enovis	$2.00B	1.33	-$33.26M	-$2.19	-21.43

Does the MarketBeat Community prefer SIBN or ENOV?

SI-BONE received 140 more outperform votes than Enovis when rated by MarketBeat users. Likewise, 68.42% of users gave SI-BONE an outperform vote while only 61.70% of users gave Enovis an outperform vote.

Company	Underperform	Outperform
SI-BONE	Outperform Votes 169 68.42%	Underperform Votes 78 31.58%
Enovis	Outperform Votes 29 61.70%	Underperform Votes 18 38.30%

Do analysts prefer SIBN or ENOV?

SI-BONE currently has a consensus price target of $23.00, suggesting a potential upside of 37.23%. Enovis has a consensus price target of $65.86, suggesting a potential upside of 40.32%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than SI-BONE.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SI-BONE	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Enovis	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Do insiders and institutionals hold more shares of SIBN or ENOV?

98.1% of SI-BONE shares are owned by institutional investors. Comparatively, 98.4% of Enovis shares are owned by institutional investors. 3.9% of SI-BONE shares are owned by company insiders. Comparatively, 2.4% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the media favor SIBN or ENOV?

In the previous week, Enovis had 5 more articles in the media than SI-BONE. MarketBeat recorded 8 mentions for Enovis and 3 mentions for SI-BONE. SI-BONE's average media sentiment score of 0.77 beat Enovis' score of 0.67 indicating that SI-BONE is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SI-BONE	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SIBN or ENOV more profitable?

Enovis has a net margin of -5.95% compared to SI-BONE's net margin of -23.82%. Enovis' return on equity of 4.39% beat SI-BONE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SI-BONE	-23.82%	-22.51%	-16.53%
Enovis	-5.95%	4.39%	2.80%

Which has more risk and volatility, SIBN or ENOV?

SI-BONE has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500.

Summary

Enovis beats SI-BONE on 9 of the 17 factors compared between the two stocks.